The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 19, 2023
Filed:
Feb. 16, 2018
Applicant:
Fred Hutchinson Cancer Center, Seattle, WA (US);
Inventors:
Stanley R. Riddell, Sammamish, WA (US);
Damian Green, Seattle, WA (US);
Tyler Hill, Seattle, WA (US);
Assignee:
Fred Hutchinson Cancer Center, Seattle, WA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/417 (2006.01); A61K 31/4245 (2006.01); A61K 31/5513 (2006.01); C07K 14/475 (2006.01); C07K 14/52 (2006.01); C07K 16/40 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 9/0053 (2013.01); A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/417 (2013.01); A61K 31/4245 (2013.01); A61K 31/5513 (2013.01); A61P 35/00 (2018.01); C07K 14/475 (2013.01); C07K 14/52 (2013.01); C07K 16/2887 (2013.01); C07K 16/40 (2013.01); A61K 45/06 (2013.01);
Abstract
The present disclosure relates to methods for using BCMA-specific binding molecules (such as a BCMA-specific chimeric antigen receptor or antibody) in combination with γ-secretase inhibitors, which can be done concurrently or sequentially, to treat or prevent a B-cell related proliferative disease, such as a cancer or autoimmune disease, or the like. A BCMA-specific binding molecule in combination with γ-secretase inhibitor can be used in, for example, adoptive immunotherapy.